Aprocitentan 
Idorsia Pharmaceuticals,Janssen
['idorsia']
we are very proud to announce that the results of our phase 3 precision study on resistant hypertension were published simultaneously in and presented at #aha22 in the late-breaking scientific session by . 
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. See our community guidelines: https://t.co/qsjMiPDfhC